Archives

Praluzatamab Ravtansine, a CD166-Targeting Antibody– Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Boni V, Fidler MJ, Arkenau HT, et al. Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial [published online ahead of print, 2022 Feb 14]. Clin Cancer Res. 2022;clincanres.3656.2021. doi:10.1158/1078-0432.CCR-21-3656

Learn More

Conditional PD-1/PD-L1 Probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti–PD 1/PD-L1 agents

Assi HH, Wong C, Tipton KA, et.al. Cancer Immunol Res. October 11 2021. DOI: 10.1158/2326-6066.CIR-21-0031

Learn More

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Sanborn RE, Hamid O, de Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002446. doi: 10.1136/jitc-2021-002446

Learn More

CX-072 (pacmilimab), a Probody®️ PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Naing A, Thistlethwaite F, De Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002447. doi: 10.1136/jitc-2021-002447

Learn More

First-in-human study of the biodistribution and pharmacokinetics of 89Zr-CX-072, a novel immunoPET tracer based on an anti-PD-L1 probody

Kist de Ruijter L, Hooiveld-Noeken JS, Giesen D, et al. [published online ahead of print, 2021 Jul 12]. Clin Cancer Res. 2021;clincanres.0453.2021. doi:10.1158/1078-0432.CCR-21-0453

Learn More

Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

Etxeberria I, Bolaños E, Teijeira A, et al. Proc Natl Acad Sci U S A. 2021;118(26):e2025930118. doi:10.1073/pnas.2025930118

Learn More

Phase 1, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Johnson M, El-Khoueiry A, Hafez N, et. al. Clin Cancer Res. June 7, 2021; doi: 10.1158/1078-0432.CCR-21-0194.

Learn More

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

Autio KA, Boni V, Humphrey RW, Naing A. Clin Cancer Res. 2020 26(5): 984-989. doi:10.1158/1078-0432.CCR-19-1457.

Learn More

Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Giesen D, Broer LN, Lub-de Hooge MN, et al. Clin Cancer Res. January 17, 2020; doi: 10.1158/1078-0432.CCR-19-3137.

Learn More

The Tumor Targeting Performance of Anti-CD166 Probody Drug Conjugate CX-2009 and its Parental Derivatives as Monitored by 89Zr-immuno-PET in Xenograft Bearing Mice

Chomet M, Schreurs M, Nguyen M, et al. Theranostics. 2020; 10(13): 5815-5828. doi:10.7150/thno.44334.

Learn More